Relmada's lead program, REL-1017, is a new chemical entity and novel NMDA receptor channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission.

REL-1017 has entered late-stage development as an adjunctive treatment for MDD in adults. In addition, Relmada is advancing a clinical-stage program in neurodegenerative diseases based on psilocybin and select derivative molecules.